HR Execs on the Move

Incyte

www.incyte.com

 
Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines that will meet serious unmet medical needs in oncology and other diseases. Incyte is a company driven by innovation, and we believe that investment in cutting-edge science and the rigorous pursuit of R&D excellence can translate into new medicines for serious unmet medical needs that positively impact patients` lives. Incyte has a diverse and growing portfolio of first-in-class and best-in-class product candidates, including both small and large molecules. Incyte is headquartered in Wilmington, Delaware with operations in 10 European countries and Japan. Our more than ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.incyte.com
  • 1801 Augustine Cut-off
    Wilmington, DE USA 19880
  • Phone: 855.446.2983

Executives

Name Title Contact Details
Bashir Ahmed
 Senior Director, R&D IT - Clinical Profile
John Krukiel
 Division Vice President US Product Strategy Profile
Marwan Sawaked
 Senior Director, R&D GMP QA Profile
Vince Fasciocco
 Head of R&D Finance Profile

Similar Companies

Center des Research Hotel-Dieu, U Laval

Center des Research Hotel-Dieu, U Laval is a Quí©bec, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Ventus Therapeutics

Ventus is a newly established venture-backed biotech company pursuing small molecule therapeutics targeting key innate immune pathways for numerous auto-immune and auto-inflammatory diseases.

Prometheus Biosciences

Prometheus Biosciences, Inc., is a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases.

Laronde

Flagship Pioneering is an American life sciences venture capital company based in Cambridge, Massachusetts that invests in biotechnology, life sciences, health and sustainability companies.

Lyndra

Lyndra Therapeutics is pioneering the first-ever oral, ultra-long-acting, sustained release therapies, which have the potential to fundamentally change the way people take medicine by enabling patients to take a pill once a week rather than daily. The Company`s breakthrough Extended-Release Oral Capsule is designed to provide consistent drug levels for an entire week or as long as a month, from one, normal-sized capsule – something no oral therapy has ever achieved before. Lyndra`s robust pipeline is made up of therapies with established and well-known safety profiles across a number of disease areas in which non-adherence is known to be a significant driver of outcomes, including schizophrenia and other central nervous system diseases, diabetes, cardiovascular disease and opioid abuse disorder, among others. The Company is also committed to advancing its platform across new chemical entities and a variety of critical global and public health opportunities alongside partners such as the Bill & Melinda Gates Foundation and the NIH.